---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-316904"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2025-12-12T23:59:59+00:00"
generated_at: "2026-05-16T13:19:45.801371+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CHMP recommends EU approval of Cytokinetics' MYQORZO for obstructive HCM

## Summary
- CHMP adopted positive opinion recommending EU marketing authorization for MYQORZO (aficamten).
- Indicated for symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy in adults.
- European Commission final decision expected in Q1 2026.
- MYQORZO is a cardiac myosin inhibitor.

## SEC filing metadata
- accession: 0001193125-25-316904
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2025-12-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000119312525316904/0001193125-25-316904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000119312525316904/cytk-20251212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-316904
- JSON: https://secwatch.observer/filing/0001193125-25-316904.json
- Plain text: https://secwatch.observer/filing/0001193125-25-316904.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.